Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Zhong, Wen-Zhao; Wang, Qun; Mao, Weimin; Xu, Lin; Wu, Lin; Wei, Yucheng; Liu, Yong-Yu; Chen, Chun; Cheng, Ying; Yin, Rong; Yang, Fan; Ren, Shengxiang; Li, Xiaofei; Li, Jian; Huang, Cheng; Liu, Zhidong; Xu, Shun; Chen, Ke‐Neng; Xu, Shidong; Liu, Lunxu; Yu, Ping; Wang, Buhai; Ma, Haitao; Yang, Jin‐Ji; Yan, Hong‐Hong; Yang, Xue‐Ning; Liu, Si‐Yang; Zhou, Qing; Wu, Yi‐Long

doi:10.1200/jco.20.01820

Public

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Published in Journal of Clinical Oncology • Dec 17, 2020

Authors:

Wen-Zhao Zhong

Qun Wang

Weimin Mao

Abstract

PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079 ), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor ( EGFR) mutatio...

Subject

Gefitinib

Medicine

Vinorelbine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!